In the crosshairs of private equity

(Full access for Lifetime Members only)

In the crosshairs of private equity

3 January 2024

What readers said about this report

"Thanks to lower interest rates combined with historically low UK stock market valuations, the time could be ripe for a rush of private equity money to bid for UK companies", one media outlet reported recently.

Indeed, Britain remains one of the world's most attractive markets for takeover bids:

  • Record-low valuations.
  • Few restrictions on foreign capital.
  • The world's sixth-largest economy.

Due to the low valuation of the overall market, bid premia in Britain have been way higher than what you'd usually find elsewhere – often 40%, 50%, or even more.

The company featured in today's report is another prime takeover target:

  • Consensus among major shareholders to sell the company.
  • Almost debt-free balance sheet.
  • Strong market share and brand.
  • Lots of recurring revenue.

Relative to other transactions in the same sector, a bid will likely have to be at least 50-75% above the current share price.

This stock has a market cap of just USD 178m.

This opportunity is exclusively available to Undervalued-Shares.com Lifetime Members.

Not a Lifetime Member yet? Sign up for a Membership - just USD 999/one-off.
Already a Lifetime Member? Log into your account to download the report.

|  What readers said about this report

Ashvin J.
January 2024

Great start to 2024 with this report.

Most recent

Latest reports (for Members only)

2-2.5x from an investment holding liquidation

2-2.5x from an investment holding liquidation

This AIM-listed small-cap will likely return all its capital to shareholders. Underresearched by investors, it's an opportunity that shouldn't even exist – but it does.

Ukraine reconstruction: one stock to benefit

Ukraine reconstruction: one stock to benefit

If or when the war in Ukraine ends, this stock will likely become the focus of investor money pushing into the country.

Actinium-225, aka "the world's rarest drug"

Actinium-225, aka "the world's rarest drug"

This little-known Western European company could become the global market leader for supplying the uber-rare "Ac-225", a potent weapon to treat cancer.